

Diana LÃ¼ftner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8383680/publications.pdf>

Version: 2024-02-01

102
papers

2,329
citations

218662

26
h-index

243610

44
g-index

137
all docs

137
docs citations

137
times ranked

2521
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBecca trial. <i>European Journal of Cancer</i> , 2022, 162, 45-55.	2.8	12
2	ABC6 Consensus: Assessment by a Group of German Experts. <i>Breast Care</i> , 2022, 17, 90-100.	1.4	6
3	Update Breast Cancer 2021 Part 4 — Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 206-214.	1.8	4
4	Update Breast Cancer 2021 Part 5 — Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 215-225.	1.8	6
5	Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib. <i>Cancer Research</i> , 2022, 82, P2-13-30-P2-13-30.	0.9	0
6	Abstract P1-18-15: Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA study. <i>Cancer Research</i> , 2022, 82, P1-18-15-P1-18-15.	0.9	0
7	Systemic therapy of metastatic breast cancer: a plea for confirmation of subtypes by genomic assays. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	0
8	Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study. <i>Clinical Colorectal Cancer</i> , 2022, 21, 244-251.	2.3	3
9	Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor—positive (HR+), human epidermal growth factor receptor-2—negative (HER2—) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1065-1065.	1.6	0
10	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics — A retrospective analysis of a real world registry. <i>European Journal of Cancer</i> , 2022, 172, 13-21.	2.8	1
11	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 108-114.	1.4	3
12	Abstract PS10-28: Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: HTA-driven analyses from the ExteNET study. , 2021, , .		0
13	Update Breast Cancer 2020 Part 5 — Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 469-480.	1.8	6
14	Neoadjuvant and adjuvant end-points in health technology assessment in oncology. <i>European Journal of Cancer</i> , 2021, 147, 40-50.	2.8	6
15	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer — Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	1.6	39
16	Update Breast Cancer 2021 Part 2 — Advanced Stages, Long-Term Consequences and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 539-548.	1.8	6
17	Update Breast Cancer 2021 Part 1 — Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 526-538.	1.8	10
18	Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment—driven analyses from the ExteNET study. <i>European Journal of Cancer</i> , 2021, 150, 268-277.	2.8	3

#	ARTICLE	IF	CITATIONS
19	New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2021, 81, 666-678.	1.8	1
20	Update Breast Cancer 2021 Part 3 â€“ Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2021, 81, 654-665.	1.8	4
21	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. European Journal of Cancer, 2021, 155, 1-12.	2.8	39
22	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 2021, 13, 4421.	3.7	12
23	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Und Frauenheilkunde, 2021, 81, 1112-1120.	1.8	17
24	Update Mammakarzinom 2021 Teil 1 â€“ PrÃvention und frÃhe Krankheitsstadien. Senologie - Zeitschrift FÃr Mammadiagnostik Und -therapie, 2021, 18, 377-390.	0.0	0
25	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers, 2020, 12, 3021.	3.7	6
26	Update Breast Cancer 2020 Part 3 â€“ Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1105-1114.	1.8	12
27	Update Breast Cancer 2020 Part 4 â€“ Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1115-1122.	1.8	11
28	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1134-1142.	1.8	4
29	Heregulin (HRC) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer, 2020, 20, 1091.	2.6	1
30	Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Targeted Oncology, 2020, 15, 467-475.	3.6	11
31	Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. Oncology Research and Treatment, 2020, 43, 628-636.	1.2	48
32	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer â€” Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast, 2020, 54, 88-95.	2.2	34
33	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clinical Research in Cardiology, 2020, 109, 1197-1222.	3.3	71
34	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus â€“ Assessment by a German Group of Experts. Breast Care, 2020, 15, 82-95.	1.4	25
35	Update Breast Cancer 2020 Part 1 â€“ Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Und Frauenheilkunde, 2020, 80, 277-287.	1.8	16
36	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care, 2020, 15, 294-309.	1.4	47

#	ARTICLE	IF	CITATIONS
37	ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019. Geburtshilfe Und Frauenheilkunde, 2020, 80, 588-600.	1.8	1
38	Update Breast Cancer 2020 Part 2 â€œ Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Und Frauenheilkunde, 2020, 80, 391-398.	1.8	12
39	Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptorâ€positive, human epidermal growth factor receptor 2â€negative locally advanced or metastatic breast cancer: Results of the singleâ€arm, phase IIIB 4EVER trial. International Journal of Cancer, 2019, 144, 877-885.	5.1	31
40	Update Breast Cancer 2019 Part 4 â€œ Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1079-1089.	1.8	18
41	Update Breast Cancer 2019 Part 5 â€œ Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1090-1099.	1.8	16
42	Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy â€œ German Expertsâ€™ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care, 2019, 14, 315-324.	1.4	9
43	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2â€positive breast cancer. European Journal of Cancer, 2019, 120, 1-9.	2.8	39
44	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care, 2019, 14, 247-255.	1.4	32
45	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care, 2019, 14, 224-245.	1.4	72
46	Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2019, 79, 591-604.	1.8	20
47	Update Breast Cancer 2019 Part 1 â€œ Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 256-267.	1.8	17
48	Update Breast Cancer 2019 Part 3 â€œ Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2019, 79, 470-482.	1.8	26
49	Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 176, 495-506.	2.5	7
50	Update Breast Cancer 2019 Part 2 â€œ Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Und Frauenheilkunde, 2019, 79, 268-280.	1.8	21
51	Approval by Authorities Does Not Allow For Suboptimal Study Conduct but Offers New Academic Possibilities. Breast Care, 2019, 14, 2-3.	1.4	0
52	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Current Opinion in Obstetrics and Gynecology, 2019, 31, 67-75.	2.0	16
53	What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?. Breast Care, 2019, 14, 10-16.	1.4	18
54	Translational Highlights in Breast and Ovarian Cancer 2019 â€œ Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1309-1319.	1.8	11

#	ARTICLE	IF	CITATIONS
55	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	3.7	43
56	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328.	2.5	40
57	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. <i>Journal of Bone Oncology</i> , 2019, 14, 100199.	2.4	3
58	Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Baseline data from the RIBANNA study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12520-e12520.	1.6	0
59	ABC4 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2018, 13, 48-58.	1.4	7
60	Update Breast Cancer 2018 (Part 1) â€œ Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	1.8	20
61	Update Breast Cancer 2018 (Part 2) â€œ Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	1.8	23
62	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€œ Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	2.2	54
63	Therapeutic approaches for protecting bone health in patients with breast cancer. <i>Breast</i> , 2018, 37, 28-35.	2.2	16
64	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	2.2	56
65	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) â€œ Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> . 2018, 78, 1056-1088.	1.8	69
66	Management of HER2-Positive Early Breast Cancer. <i>Breast Care</i> , 2018, 13, 453-455.	1.4	0
67	Update Breast Cancer 2018 (Part 4) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1119-1128.	1.8	3
68	Update Breast Cancer 2018 (Part 3) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1110-1118.	1.8	8
69	Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5865-5872.	2.0	6
70	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) â€œ Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 927-948.	1.8	59
71	Der Ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis. <i>Oncology Research and Treatment</i> , 2018, 41, 2-26.	1.2	2
72	Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 461-472.	3.9	13

#	ARTICLE	IF	CITATIONS
73	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714.	1.8	3
74	4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 469-480.	1.8	3
75	CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer. <i>Breast Care</i> , 2017, 12, 116-118.	1.4	0
76	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1239-1245.	1.7	42
77	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878.	1.8	24
78	Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 633-644.	1.8	28
79	Update Breast Cancer 2017 – Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	1.8	19
80	ABC3 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2016, 11, 61-70.	1.4	8
81	Breast cancer and bone metastases: a call for appropriate treatment. <i>Supportive Care in Cancer</i> , 2016, 24, 4075-4077.	2.2	1
82	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	2.5	27
83	Management of Metastatic Bone Disease Algorithms for Diagnostics and Treatment. <i>Anticancer Research</i> , 2016, 36, 2631-7.	1.1	37
84	Clinical Practice Guidelines for Breast Cancer: Current Limitations. <i>Breast Journal</i> , 2015, 21, 450-453.	1.0	3
85	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 41-50.	1.8	75
86	Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study. <i>Journal of Clinical Medicine</i> , 2014, 3, 883-896.	2.4	8
87	Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 115.	1.8	8
88	Benefits and Risks of Cancer Screening. <i>Oncology Research and Treatment</i> , 2014, 37, 1-1.	1.2	1
89	Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. <i>SpringerPlus</i> , 2014, 3, 328.	1.2	17
90	Health resource utilisation associated with skeletal-related events in European patients with lung cancer: ŕ subgroup analysis from a prospective multinational study. <i>Molecular and Clinical Oncology</i> , 2014, 2, 701-708.	1.0	8

#	ARTICLE	IF	CITATIONS
91	Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors. <i>Onkologie</i> , 2013, 36, 295-302.	0.8	29
92	Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration. <i>Biochemical and Biophysical Research Communications</i> , 2011, 414, 226-232.	2.1	10
93	Association of IL-6, Hypothalamus-Pituitary-Adrenal Axis Function, and Depression in Patients With Cancer. <i>Integrative Cancer Therapies</i> , 2010, 9, 270-275.	2.0	50
94	Plasma HER2 levels are not associated with cardiac function or hypertrophy in control subjects and heart failure patients. <i>International Journal of Cardiology</i> , 2010, 145, 105-106.	1.7	4
95	Serum HER2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. <i>Cancer</i> , 2008, 113, 1294-1301.	4.1	94
96	Prescription Pattern of Aromatase Inhibitors for the Adjuvant Therapy of Breast Cancer in Germany – Results of the Second Survey Among Gynaecologists and Medical Oncologists. <i>Onkologie</i> , 2008, 31, 19-25.	0.8	2
97	Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3394-3400.	1.6	355
98	Pegfilgrastim – Rational Drug Design for the Management of Chemotherapy-Induced Neutropenia. <i>Oncology Research and Treatment</i> , 2005, 28, 595-602.	1.2	1
99	Prescription Pattern of Aromatase Inhibitors in the Adjuvant Setting in Germany – Final Results of a Survey Among German Breast Cancer Specialists. <i>Oncology Research and Treatment</i> , 2005, 28, 639-644.	1.2	3
100	Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. <i>Breast Cancer Research</i> , 2005, 7, R436-43.	5.0	130
101	Serum HER-2/neu in the management of breast cancer patients. <i>Clinical Biochemistry</i> , 2003, 36, 233-240.	1.9	42
102	Nuclear matrix proteins as biomarkers for breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2002, 2, 23-31.	3.1	22